0
     

Report Added
Report already added
Sedation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Sedation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 2, 1 and 3 respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sedation - Overview
Sedation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Sedation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sedation - Companies Involved in Therapeutics Development
Chengdu List Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
JOS Pharmaceuticals Ltd
Melt Pharmaceuticals Inc
PAION AG
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Prime Pharmaceutical Co Ltd
Sedation - Drug Profiles
(ketamine + midazolam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
ciprofol - Drug Profile
Product Description
Mechanism Of Action
History of Events
dexmedetomidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
EL-001 - Drug Profile
Product Description
Mechanism Of Action
etomidate hydrochloride - Drug Profile
Product Description
Mechanism Of Action
midazolam ODT - Drug Profile
Product Description
Mechanism Of Action
remimazolam besylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Sep 16, 2021: Acacia Pharma announces initiation of pivotal study of Byfavo in pediatric procedural sedation
Sep 02, 2021: Acacia Pharma to host webinar with Key Opinion Leaders to discuss the hospital user experience with Byfavo
Sep 02, 2021: Clinigen signs exclusive UK supply and distribution agreement with PAION
Aug 31, 2021: Paion: Hana Pharm receives market approval for Byfavo (Remimazolam) in procedural sedation In South Korea
Aug 16, 2021: Paion launches Byfavo (Remimazolam) in the UK for procedural sedation
Jul 09, 2021: Paion announces that NMPA accepts submission Of New Drug Application For remimazolam besylate in general anesthesia By Chinese Licensee Yichang Humanwell
Jul 01, 2021: Acacia Pharma: Significant continued progress with formulary uptake of BYFAVO in the US
Jun 29, 2021: Paion receives UK MHRA approval of Byfavo (Remimazolam) for procedural sedation
Apr 07, 2021: Paion announces product launch Of Byfavo (Remimazolam) in South Korea by Hana Pharm
Feb 09, 2021: Melt Pharmaceuticals completes phase 1 study for sublingual, non-opioid pain and sedation drug candidate
Jan 28, 2021: Acacia pharma launches BYFAVO(remimazolam) in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less
Jan 28, 2021: CHMP recommended granting a marketing authorisation for Byfavo (remimazolam) for procedural sedation
Jan 07, 2021: Paion: Hana Pharm receives market approval For Remimazolam (Byfavo) in general anesthesia In South Korea
Dec 15, 2020: Acacia Pharma announces amendment of its investment agreement with Cosmo Pharmaceuticals for BYFAVO
Dec 14, 2020: National Food and Drug Administration approves the marketing of cyclopofol injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sedation, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Sedation - Pipeline by Chengdu List Pharmaceutical Co Ltd, 2022
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2022
Sedation - Pipeline by JOS Pharmaceuticals Ltd, 2022
Sedation - Pipeline by Melt Pharmaceuticals Inc, 2022
Sedation - Pipeline by PAION AG, 2022
Sedation - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
Sedation - Pipeline by Sichuan Prime Pharmaceutical Co Ltd, 2022
Sedation - Dormant Projects, 2022
Sedation - Discontinued Products, 2022

List of Figures
Number of Products under Development for Sedation, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Sedation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline